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Edited by Miguel De la RosaAbstract Epstein-Barr virus (EBV) is an omnipresent human
virus causing infectious mononucleosis and EBV associated can-
cers. Its protease is a possible target for antiviral therapy. We
studied its dimerization and enzyme kinetics with two enzyme
assays based either on the release of paranitroaniline or 7-amino-
4-methylcoumarin from labeled pentapeptide (Ac-KLVQA) sub-
strates. The protease is in a monomer–dimer equilibrium where
only dimers are active. In absence of citrate the Kd is 20 lM
and drops to 0.2 lM in presence of 0.5 M citrate. Citrate
increases additionally the activity of the catalytic sites. The
inhibitory constants of diﬀerent substrate derived peptides and
a-keto-amide based inhibitors, which have at best a Ki of
4 lM, have also been evaluated.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Human herpesviruses are divided into three sub-families, the
a-herpesviruses: herpes simplex viruses (HSV) 1 and 2, and
Varicella zoster virus (VZV), the b-herpesviruses: cytomegalo-
virus (CMV) and human herpesvirus (HHV) 6 and 7, and
the c-herpesviruses: Kaposi’s sarcoma-associated herpesvirusAbbreviations:Ac, acetyl; Aca, 6-aminocaproic acid; AMC, 7-amino-4-
methylcoumarin; Boc, tert-butyloxycarbonyl; DLS, dynamic light
scattering; DMF, dimethylformamide; DMSO, dimethylsulfoxide;
EBV, Epstein-Barr virus; Fmoc, N-(9-ﬂuorenyl)methoxycarbonyl; H-
BTU, N-[(1H-benzotriazol-1-yloxy) (dimethylamino)methylene]-N-m-
ethylmethanaminium hexaﬂuorophosphate; HSV, herpes simplex
virus; HHV, human herpesvirus; KSHV, Kaposi’s sarcoma-associated
herpesvirus; MALLS, multi-angle laser light scattering; pNA, para-
nitroaniline; TFA, triﬂuoroacetic acid; VZV, varicella zoster virus
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doi:10.1016/j.febslet.2006.11.006(KSHV or HHV8) and Epstein-Barr virus (EBV). The latter
infects the vast majority of the world’s population. After pri-
mary infection, which has no characteristic symptoms and
often goes unrecognized if it occurs early in childhood, EBV
establishes and maintains a lifelong persistence in the infected
host. If the primary infection occurs during adolescence or
adulthood it often appears as infectious mononucleosis. The
majority of its cases recover uneventfully but serious complica-
tions (hemophagocytic syndrome, neurologic complications,
spleenic rupture or severe airway obstruction, long lasting
fatigue) may occur and fatal outcomes of infectious mononu-
cleosis have been described in immunocompromised and
immunocompetent hosts. Due to higher hygiene in developed
countries, this delayed primary infection is globally gaining
importance. Furthermore EBV can lead to EBV-induced
malignant B-cell lymphoma in immunosuppressed patients,
and is implicated to diﬀerent degrees in the pathogenesis of
several cancers in the immunocompetent population such as
Burkitt’s lymphoma, nasopharyngeal carcinoma and gastric
carcinoma (see [1] for a recent review). EBV shares this onco-
genic potential with KSHV.
During latency, only a limited set of reading frames is
expressed, whereas the lytic cycle is characterized by the
expression of the full set of viral proteins needed for viral rep-
lication, such as the DNA polymerase and the late structural
proteins including the protease. The lytic cycle of EBV infec-
tions is active in infective mononucleosis where shedding of
infectious virus lasts much longer than the actual disease [2].
The currently licensed antiviral drugs against human herpesvi-
ruses inhibit the viral DNA polymerases. These are either acy-
clovir and related compounds, or foscarnet or cidofovir. These
drugs are thus directed against the lytic cycle of the viral infec-
tion, principally of herpes simplex virus and CMV, but some
may still have an eﬀect in a number of cases of EBV related
immunoproliferative disease [3], despite a controversial role
of the contribution of the lytic cycle to this syndrome.
Herpesvirus proteases are essential for the production of
infectious virions. They disrupt the scaﬀold formed by the
assembly protein after assembly of the capsid in order to make
space for the viral DNA. They are synthesized as part of a
polyprotein comprising the protease domain and the assembly
protein domain, whereas individual assembly protein mole-
cules are also translated from a second overlapping reading
frame [4]. The protease mainly recognizes two types of se-
quence, the maturation (M) site close to the C-terminus of
the assembly protein domain and the release (R) site betweenblished by Elsevier B.V. All rights reserved.
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teases form a class of serine proteases with a catalytic triad
composed of Ser-His-His. They exist in a monomer–dimer
equilibrium in vitro where only the dimer is active [5–7]. X-
ray crystallographic studies on the protease from CMV,
HSV1, HSV2, VZV, KSHV and EBV have shown the presence
of a conserved dimer structure [8–14].
Despite extensive studies on the herpesvirus proteases of
HSV, CMV and VZV [15], no active-site based inhibitors have
entered clinical trials yet. Some sub-micromolar peptide-based
inhibitors against CMV protease have been reported [16,17].
Drug development has certainly been hampered by the shallow
active site of the herpesvirus proteases, leading to a search for
new approaches for antiviral action on these molecules, such as
dimer disruption. A peptide derived from the interface helices
of KSHV showed a limited eﬃciency as its Ki is in the range of
300 lM [18].
The eﬀect of kosmotropic (anti-chaotropic) salts, glycerol or
sucrose on the activity of herpesvirus protease has been studied
[6,19,20] and they are commonly used in order to enhance the
protease activity in assays. Examples are the use of 25%
glycerol for HSV1 protease [21], 0.5 M Na2SO4 and 10% glyc-
erol for CMV [17], 30% sucrose for CMV [22], 0.8 M potas-
sium phosphate and 25% glycerol for KSHV protease [23].
As most of the enzymological studies have been done in the
presence of such agents little kinetic data has been determined
in their absence. The mechanism of this activation goes along
with a promotion of dimerization but has not been studied in
detail.
So far, the EBV protease has been the least studied of this
group of enzymes. The monomer–dimer equilibrium of EBV
protease has been studied by Buisson and coworkers [24], who
also described an optimal heptapeptide substrate. The structure
of EBV protease was solved by X-ray crystallography [14].
In the prospect of designing inhibitors directed against the
EBV protease, our test for enzymatic activity based on a chro-
mogenic substrate [14] has been adapted for use within a
96-well plate reader and the EBV protease activity has been
quantiﬁed in the absence or presence of citrate. We found that
citrate promotes dimerization and stimulates activity. These
ﬁnding have been conﬁrmed using a ﬂuorogenic substrate
based on the release of 7-amino-4-methylcoumarin (AMC).
The inhibitory constants of diﬀerent peptides derived from
the recognition site and peptide-based inhibitors containing
an a-keto-amide moiety have been determined.Table 1
Summary of the diﬀerent compounds tested in this study and their inhibitio
Inhibitor Deﬁnition
1 Ac-KLVQASA-NH2 M-site, positions P5–P2
2 Aca-LVQA-NH2 M-site, positions P5–P1
3 Ac-SYLKA-OH R-site, positions P5–P1
4 Aca-LVQA-CONH2 a-Keto-amide inhibitor
5 Aca-LVQA-CO-D-Phe-NH2 a-Keto-amide inhibitor
with an hydrophobic si
6 Aca-LVQA-CO-Phe-NH2 a-Keto-amide inhibitor
with an hydrophobic si
7 Aca-LVQA-CO-Ser-NH2 a-Keto-amide inhibitor
8 Aca-LVQA-CO-Ser-Ala-NH2 a-Keto-amide inhibitor
ZnSO4 Cysteine-histidine ligan
aObtained with the chromogenic assay.
bObtained with the ﬂuorogenic assay.2. Materials and methods
tert-Butyloxycarbonyl (Boc)- and Fmoc-aminoacids, N-[(1H-benzo-
triazol-1-yloxy) (dimethylamino)methylene]-N-methylmethanaminium
hexaﬂuorophosphate (HBTU) and resins were purchased from Senn
Chemicals International (Gentilly, France) or Advanced ChemTech
(Louisville, USA). The reagents and solvents for the solid phase syn-
thesis were obtained from Acros (Noisy-le-Grand, France) or Sigma-
Aldrich Fine Chemicals (Saint Quentin Fallavier, France) and were
used without additional puriﬁcation. All other chemicals were of the
purest grade available. The peptides 1–3 (Table 1) were synthesized
as described [24].
2.1. Synthesis of the a-keto-amide inhibitors, 4–8
Compounds 4–8 (Table 1) are derived from the sequence P5–P1
(nomenclature of Schechter and Berger [25]; sequence Lys-Leu-Val-
Gln-Ala) of the M site, with or without added P1 0 and/or P2 0 residues.
The P5 lysine residue was replaced by 6-aminocaproic acid or desa-
mino-lysine (Aca), which confers resistance to aminopeptidases. P1
Ala was replaced by its a-keto-acyl derivative (‘‘Ala-CO’’). The P1 0
residue is either the wild-type Ser residue (compounds 7 and 8) or an
hydrophobic phenylalanine residue (compounds 5 and 6). The
activated carbonyl component was obtained from the corresponding
a-hydroxy acid (norstatine derivative of alanine). The Fmoc protected
a-hydroxy acid derivative of alanine was synthesized in ﬁve steps from
Boc-Ala-OH. The ﬁrst two steps (i.e. coupling of Boc-Ala-OH to O,N-
dimethylhydroxylamine and reduction of the formed Weinreb amide
using LiAlH4) led to the aldehyde Boc-Ala-H and were performed as
described [26]. The aldehyde was then reacted with KCN (4 equiv.)
in ethylacetate:water:methanol (5:2.5:2.5) for four days at room tem-
perature. The obtained cyanohydrine was hydrolysed (removing at
the same time the Boc protecting group) by treatment with conc.
HCl (10 ml per g) for three days at room temperature, giving the
deprotected norstatine derivative. N-(Fmoc-oxy)-succinimide was used
for protection. The inhibitor sequences were assembled stepwise by
hand on a Rink amide resin using Fmoc chemistry. Couplings were
performed in dimethylformamide (DMF) using HBTU in the presence
of diisopropylethylamine. Finally, Boc-protected Aca was introduced.
Once the assembly was complete, oxidation of the hydroxy group to
ketone was performed on the resin using Dess-Martin periodinane
(2 equiv. in dimethylsulfoxide (DMSO), overnight). Then, deprotec-
tion and cleavage from the resins were carried out by treatment with
triﬂuoroacetic acid:tris-isopropylsilane:H2O (9.5:0.25:0.25, 10 ml/g re-
sin, 2 h). The crude products were puriﬁed by reverse-phase HPLC
on a C18 column (Deltapack Waters 40 · 100 mm) by means of a lin-
ear gradient of acetonitrile in 0.1% aqueous triﬂuoroacetic acid over
25 min (ﬂow rate 28 ml/min). Their purity and identity were assessed
by reverse-phase HPLC and electrospray mass spectrometry (4, exper-
imental mass, 569.3 ± 0.2 u; calculated mass, 569.3 u; 5, exp. mass,
716.4 ± 0.2 u; calc. mass, 716.4 u; 6, exp. mass, 716.3 ± 0.2 u; calc.
mass, 716.4 u. 7, exp. mass, 656.4 ± 0.2 u; calc. mass, 656.4 u. 8, exp.
mass, 727.4 ± 0.2 u; calc. mass, 727.4 u.). For each compound, a sec-
ond mass M+18 u was observed and corresponds to the hydrated form
of the activated keto group.n constant
Ki (lM)
0 24a
4100a
1200a
based on M-site, positions P5–P1 3.7a, 4b
based on M-site, positions P5–P10,
de chain at P1 0 position
20b
based on M-site, positions P5–P10,
de chain at P1 0 position
5b
based on M-site, positions P5–P10 200b
based on M-site, positions P5–P20 65b
d 1700a
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The puriﬁcation of the EBV protease domain, Pr-wt, was performed
as described [14,24]. The EBV protease activity was determined by
monitoring the cleavage of Ac-KLVQA-pNA, a chromogenic sub-
strate derived from the M site peptide of EBV assembly protein cou-
pled with paranitroaniline as described previously [14]. The assay
was performed at 25 C and pH 7.5 in a buﬀer composed of 20 mM
Tris and 80 mM NaCl. Whenever indicated, 0.5 M sodium citrate
was added. The absorption of free paranitroaniline (pNA), produced
by the hydrolysis of the paranitroanilide substrate, was followed spec-
trophotometrically at 405 nm using a 96-well microplate reader
(IEMS, ThermoLabsystem). The amount of hydrolyzed substrate
was calculated using a calibration with free pNA (Sigma-Aldrich) in
assay buﬀer. For 200 ll/well the conversion factor was 5.9 AU mM1
independently of the presence of citrate.
2.3. Kinetic studies using the chromogenic substrate
The enzyme was pre-incubated for 15 min at 25 C in the assay buf-
fer before addition of the substrate. The speciﬁcity constant kcat/Km
and the individual parameters Km and kcat for the chromogenic sub-
strate were determined from initial rate kinetics by a ﬁt of the Michae-
lis–Menten equation using XPLOT [27]. Only the initial linear part of
the plot of absorption versus time has been used. In the absence of
citrate, the assay included 0.5 mg/ml bovine serum albumine (Roche
Diagnostics) and the time course lasted for 7 h, whereas in the presence
of citrate, the time course lasted for 3 h 30 min at maximum. Experi-
ments for the determination of the initial rate as a function of the
protein concentration were carried out in duplicate. Series (3–6) of
experiments were used for the calculation of the kinetic constants.
2.4. Fluorogenic assays
The substrate Ac-KLVQA-AMC has been synthesized in the follow-
ing manner: the protected fragment Ac-Lys(Boc)-Leu-Val-Gln(Trt)-
OH was assembled on a chlorotrityl resin following Fmoc strategy
and using HBTU as the coupling agent. The protected peptide was
released from the solid support with the help of a dichloromethane:tri-
ﬂuoroethanol:AcOH (7:2:1) mixture (1 h, then 10 min) and used
without puriﬁcation for the following step. The second fragment,
Ala-AMC (TFA salt), was prepared by coupling Boc-Ala-OH to AMC
(1.2 equiv.) in the presence of di-tert-butyldicarbonate (1.2 equiv.) in
dioxane:pyridine (10:0.2), followed by Boc removal using TFA. The
two fragments (1 equiv. each) were then condensed in DMF in
the presence of N-[(1H-7-azabenzotriazol-1-yloxy) (dimethylamino)-
methylene]-N-methylmethanaminium hexaﬂuorophosphate (HATU,
1.1 equiv.) and diisopropylethylamine (3 equiv.) for 30 min. The pro-
tected ﬂuorogenic substrate was ﬁnally treated with a mixture of
TFA:triisopropylsilane:water (95:2.5:2.5) for 1 h to yield the expected
compound, which was puriﬁed by reverse-phase HPLC. Its purity
and identity were assessed by reverse-phase HPLC and electrospray
mass spectrometry (exp. mass, 756.3 ± 0.2 u; calculated mass, 756.3 u).
The release of AMC has been monitored in a 96-well ﬂuorescence
plate reader (Wallac 1420) with an excitation wavelength of 355 nm
at an emission wavelength of 460 nm. The linearity of the response
was veriﬁed and the assay calibrated using diﬀerent dilutions of
AMC (Sigma-Aldrich). The substrate concentration was veriﬁed after
full hydrolysis. Assays were carried out at 25 C. We used a 0.2 mM
stock solution of the substrate in water in order to avoid interference
of other solvents with the dimerization of the protease. The substrate
concentration was limited by its poor solubility. Diﬀerent protease
dilutions in 0.1 ml of a twice concentrated buﬀer were prepared in
black 96-well plates (BD Falcon, Microtest ﬂat bottom, standard sur-
face) starting from buﬀers containing 0 M or 1 M sodium citrate,
160 mM NaCl and 40 mM Tris–HCl at a pH of 7.5. The reaction
was started by the addition of 0.1 ml substrate using a multichannel pi-
pet and the plates were read immediately by the plate reader. Kinetics
were monitored and the points with a substrate cleavage <20% were
used in order to calculate initial rates.
2.5. Modelling of the monomer–dimer equilibrium
The concentration of the protease dimer is given by:
½Pr2 ¼ Kd
8
1þ 4½E
Kd

ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
1þ 8½E
Kd
s !
ð1Þwhere [E] is the total protease concentration (expressed as monomers)
and Kd the dissociation constant of the monomer–dimer equilibrium.
The speciﬁc activity
vi=½E ¼ a0f ¼ a0 2 Pr2½ ½E ð2Þ
is proportional to the fraction f of functional active sites, where a0 cor-
responds to the maximal value of vi/[E]. Eq. (2) was ﬁtted to the exper-
imental points using XPLOT [27], where Kd and a0 have been adjusted.
2.6. Dynamic light scattering
Samples were centrifuged for 10 min at 13000 rpm in an Eppendorf
centrifuge in order to eliminate coarse aggregates and dust. Dynamic
light scattering experiments used a Dynapro apparatus (ProteinSolu-
tions) with a temperature regulated 15 ll cuvette. Measurements were
taken at 25 C and data were analyzed using the Dynamics v5.26.41
software. Poorly determined initial measurements were rejected based
on the ‘‘baseline limit’’ parameter. Theoretical values for Stokes’ radii
of monomers and dimers have been calculated from the 3-dimensional
structure of the protease (pdb entry 1O6E, [14]) using the software
HYDROPRO [28].
2.7. Size exclusion chromatography and multi-angle laser light scattering
Size exclusion chromatography was performed with a Shodex Pro-
tein KW-804 HPLC column (300 mm · 8.0 mm). The column was
equilibrated in 20 mM Tris–HCl, 80 mM NaCl buﬀer at pH 7.5 in
the absence or presence of 500 mM sodium citrate. Separations were
performed at 20 C with a ﬂow rate of 0.8 ml min1. Stokes’ radii were
determined by calibrating the column with globular proteins of known
Stokes’ radius. On-line detection was performed by multi-angle laser
light scattering (MALLS) using a DAWN-EOS detector (Wyatt Tech-
nology Corp., Santa Barbara, CA) equipped with a laser emitting at
690 nm and by refractive index measurement using a RI2000 detector
(Schambeck SFD). Light scattering intensities were measured at diﬀer-
ent angles relative to the incident beam, and analysis of the data was
performed with the ASTRA software (Wyatt Technology Corp., Santa
Barbara, CA). The excess light scattering intensity at angle h (Rh) is
related to molecular mass of solute particle according to Zimm’s
formalism of the Rayleigh–Debye–Gans model for a diluted polymer
solution [29]. For small (gyration radius smaller than 100 nm), non-
interacting particles Rh is given by
Rh
KC
¼ M ð3Þ
where Rh is the measured excess Rayleigh ratio, C is the protein con-
centration (g ml1) as measured by on-line refractive index detector,
M is the molar mass (g mol1), and K* is an optical constant given
by the following equation:
K ¼ 1
NA
2pn0
k2
 2
dn
dc
 2
ð4Þ
where NA is Avogadro’s number, n0 is the refractive index of the sol-
vent at the incident radiation wavelength (1.33 for a diluted aqueous
buﬀer), dn/dc (ml g1) is the speciﬁc refractive index increment of the
solute (0.185 ml g1), and k is the wavelength of the incident light in
void (690 nm). Within the elution peak, the chromatogram is divided
in slices, and for each slice, MALLS and refractive index measure-
ments are used to calculate the molecular weight. Number-averaged
(Mn) and weight-averaged (Mw) molecular weights are obtained from
the molecular weight distribution across the elution peak.
2.8. Competition of inhibitors with the chromogenic substrate
Experiments were carried out in the presence of 0.5 M citrate using a
protease concentration of 0.2 lM and a preincubation time of 30 min
with the inhibitor (except for compound 1, which is a substrate). Con-
centrations were as follows: compound 1 (Ac-KLVQASA-NH2),
0.001–0.1 mM, substrate between 0 and 0.4 mM; compound 2 (Aca-
LVQA-NH2), 0.5, 0.75 and 1 mM, substrate between 0 and 0.1 mM;
compound 3 (Ac-SYLKA-OH) 0.3–0.6 mM, substrate between 0 and
0.15 mM; compound 4 (Aca-LVQA-CONH2), 0.001–0.2 mM, sub-
strate between 0 and 0.15 mM; ZnSO4, 0.01, 0.1 and 1 mM, substrate
between 0.05 and 0.4 mM. Cornish–Bowden plots were used to verify
competitive inhibition and Kis were derived from Dixon plots.
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M. Buisson et al. / FEBS Letters 580 (2006) 6570–6578 65732.9. Competition of inhibitors 4–8 with the ﬂuorogenic substrate
Inhibitors and substrate were solubilized in DMSO to stock concen-
trations of 10 mM. Diﬀerent ﬁnal inhibitor concentrations ranging
from 0.2 lM to 500 lM were used in the assay. Inhibitors in 10 ll
DMSO were added to 95 ll of buﬀer (0.5 M sodium citrate, 80 mM
NaCl and 20 mM Tris–HCl at a pH of 7.5) containing the enzyme.
95 ll of substrate solution using the same buﬀer have been added to
start the reaction (12.5–37.5 lM ﬁnal) leading to a ﬁnal concentration
of the enzyme of 0.2 or 0.3 lM. The substrate concentration was lim-
ited by its solubility. The ﬂuorescence change was measured as de-
scribed above. The initial linear part of the time-course was used for
rate determinations. Inhibition constants were determined from Dixon
plots.0
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Fig. 1. Speciﬁc activity of EBV protease determined by colorimetry as
a function of its concentration. Values obtained for substrate
concentrations of 100 lM (squares) or 50 lM (triangles). (A) In the
absence of citrate. The theoretical curve given by Eq. (2) based on the
assumption of a monomer–dimer equilibrium with inactive monomers
and a Kd of 18 lM is shown as solid line. (B) In the presence of 0.5 M
citrate. The theoretical curve corresponds to a Kd of 0.2 lM.3. Results
3.1. Determination of the dissociation constant of the protease
dimer in the absence and presence of citrate from the
enzymatic activity
First the chromogenic substrate (Ac-KLVQA-pNA) was
used and the liberation of pNA was followed spectrophoto-
metrically using a 96-well plate reader. As herpesvirus protease
monomers are inactive [5–7], determining the speciﬁc activity
vi/[E] as a function of the protease concentration should allow
to determine the dissociation constant Kd of the protease di-
mer. When vi/[E] was plotted as a function of the total concen-
tration of protease monomers [E] (Fig. 1A), the data points
could be ﬁtted by a theoretical curve based on a simple mono-
mer–dimer equilibrium where monomers were inactive as de-
scribed in the Section 2. This yielded a dissociation constant
of 18 ± 3 lM for the protease dimer.
Using the ﬂuorogenic substrate (Ac-KLVQA-AMC) a disso-
ciation constant of 20 ± 2 lM was obtained under the same
conditions (Fig. 2A).
The chromogenic assay in the presence of 0.5 M sodium cit-
rate showed a shift of the dissociation constant to 0.2 lM
(Fig. 1B). But data points scatter considerably at low activity
due to a lack of sensitivity whereas values for enzyme concen-
trations above 0.5 lM have a tendency to level oﬀ more rap-
idly than the theoretical curve limiting the precision of the
obtained dissociation constant.
As the enzyme concentration is imposed, the large dynamic
range of the enzymatic activity in function of protease and cit-
rate concentrations is an experimental challenge. In order to
overcome the sensitivity limitations of the assay, the same
experiment was carried out using the ﬂuorogenic substrate.
A Kd of around 0.4 lM was obtained (Fig. 2A) although the
increase of the assay sensitivity was not as large as expected
due to drifts of the baseline ﬂuorescence signal. Again, at high
protease concentrations, the speciﬁc activity has a tendency to
be lower than expected. This strongly aﬀects the ﬁt of the the-
oretical curve and creates an uncertainty of the value for Kd,
which is comprised between 0.1 and 0.8 lM.
In order to further characterize the eﬀect of citrate, we deter-
mined the speciﬁc activity of the enzyme at diﬀerent enzyme
and citrate concentrations (Fig. 2A). In general, speciﬁc activ-
ities seemed to level oﬀ for high enzyme concentrations at cit-
rate concentrations above 250 mM, where the theoretical curve
no longer ﬁts well. At low citrate concentrations, the ﬁt of the
experimental points to the theoretical curve is excellent over a
large range of protease concentrations. The experiments at
variable citrate concentrations show that the dissociation con-
stant dropped already at citrate concentration as low as30 mM and reaches a plateau value for 250 mM citrate
(Fig. 2B). In parallel there is an eﬀect on the maximal speciﬁc
activity a0 obtained from the ﬁt of Eq. (2) as shown in Fig. 2C
which rises continuously, in particular at high citrate concen-
trations (Fig. 2C).
3.2. Oligomerization state of the protease in the absence or
presence of citrate
When we used dynamic light scattering (DLS), the scattered
signal for equivalent concentrations of the protease was much
higher in the presence of 0.5 M citrate than at in its absence
(Fig. 3A). The detection of the protease was still possible at
concentrations where it does not yield any measurable signal
in the absence of citrate. This indicates the presence of an
aggregated form of the protease in the presence of citrate even
at very low enzyme concentrations. Determination of the size
of these aggregates by DLS was impossible, suggesting rather
an aggregation than an oligomerisation with a deﬁned particle
size. When a sample containing 0.5 M citrate was diluted step-
wise, the aggregates disappeared between concentrations of
0.25 M and 0.125 M and a species with a size between those
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Fig. 2. Speciﬁc activity of EBV protease determined by ﬂuorimetry in
function of protein and citrate concentrations. (A) Series of experi-
ments at diﬀerent concentrations of citrate (from the bottom: 30, 60,
125, 250, 375, and 500 mM) and 100 lM substrate. Theoretical curves
(see Section 2) are shown as thin lines. (B) The Kd of the dimer in
function of the citrate concentration. Individual points represent
individual experiments. The thin line passes through the average. Open
squares indicate values determined with a substrate concentration of
25 lM, ﬁlled rhombuses values obtained at 100 lM. (C) Maximal
value of vi/[E] as obtained from the curve ﬁtting as shown in Fig. 2A in
function of the citrate concentration. The thin lines correspond to
second-order polynomials. Substrate concentration: 25 lM, open
squares; 100 lM, ﬁlled rhombuses.
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Fig. 3. Aggregation of the protease. (A) Double logarithmic plot of
the scattered intensity in a DLS experiment in function of the protease
concentration. Triangles represent points measured in the absence of
citrate, squares in the presence of 0.5 M citrate. (B) Run of the
protease (injected concentration 18.5 mg ml1) over a size-exclusion
HPLC column coupled with a static light scattering apparatus and a
refractometer. Continuous line: change of the refractive index in
absence of citrate (1) and in presence of citrate (2). The negative peak is
due to a mismatch between the buﬀer used in the experiment and the
one present in the protein sample. Data points: molecular weight
calculated from the scattered intensity and the refractive index change
in presence of 0.5 M citrate (1) and in its absence (2). The measured
signal is converted into the refractive index change after multiplication
with a constant a = 9.6 Æ 105 V1.
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shown).
In the absence of citrate, a concentration dependent average
Stokes’ radius of the molecule between 2.6 and 3.4 nm was ob-
served (not shown). For comparison, the theoretical values for
monomers and dimers derived from the 3-dimensional struc-
ture of the protease, pdb entry 1O6E, [14], without taking into
account its hydration, are 2.6 and 3.3 nm, respectively. In addi-
tion, in the absence of citrate the amplitude of the scattered
signal is in agreement with the one expected for a protein of
the size of the protease (Fig. 3A). On a HPLC SEC sizing col-
umn, in the absence of citrate, the protease elutes in a major
peak with Stokes’ radius of 3.2 nm and a shoulder with a
Stokes’ radius of approximately 4.0 nm (Fig. 3B). Detection
by multi-angle laser light scattering and refractive index indi-
cated that, in the absence of citrate, the diﬀerent components
have in majority (85%) an average molecular weight of
45 kDa (expected 52 kDa for a dimer), with a small proportion
of trimer (11%) with a mass of 83 kDa (expected 77 kDa) and
an even smaller proportion (4%) of higher molecular weight
species. In the presence of 0.5 M citrate, the protease is re-
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M. Buisson et al. / FEBS Letters 580 (2006) 6570–6578 6575tarded on the SEC column and elutes in the same volume as
small molecules such as citrate, and the refractive index mea-
surement is contaminated by the change in the refractive index
caused by the mismatch of the citrate concentration between
protein sample and buﬀer. Only in the ﬁrst part of the elution
peak the refractive index can be measured accurately. Despite
of the above mentioned aggregates, most of the enzyme was
still present in solution (>30% of the protein input are found
in the half peak). The average molecular weight Mw varies
from 70 kDa to 200 kDa in the left half of the peak, suggesting
diﬀerent oligomeric species (Fig. 3B) in addition to dimers and
monomers which could not been measured due to the refrac-
tive index mismatch between protein solution and buﬀer. As
judged from the refractive index measurement, large aggre-
gates correspond to only a small fraction of the total mass of
the protein.[S] (mM)
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Fig. 4. Michaelis–Menten plots using the chromogenic Ac-KLVQA-
pNA substrate. (A) Example of a plot of vi/[E] versus [S] in the absence
of citrate. Enzyme concentrations are 20 lM, diamond; 10 lM,
squares; and 5 lM, triangles. Theoretical Michaelis–Menton curves
with a Km = 2.6 mM are shown. (B) Plot of vi/[E] versus [S] in the
presence of 0.5 M citrate at diﬀerent enzyme concentrations (0.3,
triangle; 0.5, square; 2, empty triangle; 10 lM, empty square). The
theoretical Michaelis–Menten curve (solid line) uses the average values
of Km = 0.9 mM and kcat = 14 min
1.
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chromogenic assay
The kinetic constants of the protease using Ac-KLVQA-
pNA in the absence and in the presence of 0.5 M citrate were
derived from Michaelis–Menten plots. Because of the poor sol-
ubility of the substrate, it was impossible to measure initial
rates at substrate concentrations higher than 0.4 mM, a value
well below the Km of the enzyme and the accuracy of the values
for Km and kcat is rather low, whereas a more accurate value
can be obtained for kcat/Km derived from the initial slope of
the Michaelis–Menten plots (Fig. 4).
In the case of an enzyme submitted to a monomer–dimer
equilibrium, we obtained an apparent value for kcat as only a
fraction of the enzyme is dimeric and thus active. Using the
calculated concentration of the dimer and its Kd determined
previously, a ktrue value can be calculated, which we deﬁne
as the catalytic rate of one active site of a protease dimer. In
the absence of citrate, we obtained ktrue = 2.5 ± 0.6 min
1
and Km = 2.6 ± 0.4 mM. For ktrue/Km we obtained 0.95 ±
0.08 min1 mM1 from Michaelis–Menten plots (Fig. 4A).
In the presence of 0.5 M citrate we obtained kcat and Km val-
ues of 14 ± 2 min1 and 0.9 ± 0.2 mM, respectively. The deter-
mination of Km is rather inaccurate, but the increased Km
compared to the one in presence of citrate becomes obvious
from the lower curvature of the plots in Fig. 4A compared
to 4B. For kcat/Km we obtained 16.4 ± 0.7 min
1 mM1 from
the initial slope. Although four diﬀerent enzyme concentra-
tions between 0.3 and 10 lM have been used in this experi-
ment, the experimental points for vi/[E] superpose (Fig. 4B).
This shows rather an independence of the kinetic parameters
from the protease concentration as observed as well in Figs.
1B and 2A and is unexpected for an enzyme subject to a mono-
mer–dimer equilibrium. As the fraction of active catalytic sites
could not be predicted accurately, we resigned to calculate the
ktrue value as for the equilibrium in the absence of citrate.-2000.00
0.00
2000.00
-0.01 -0.005 0 0.005 0.01 0.015 0.02
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Fig. 5. Dixon plot of the inhibition by the a-keto-amide inhibitor,
compound 4, in the colorimetric assay. Diﬀerent series correspond to
diﬀerent substrate concentrations. The intersection yields the compet-
itive inhibition constant Kic = 3.7 lM.3.4. Inhibition of EBV protease
In order to reduce the consumption of enzyme, further
experiments were carried out in the presence of citrate. First,
as Zn2+ ions have been described to be eﬃcient inhibitors of
CMV protease [22] we tested ZnSO4, which appeared to be
only a poor inhibitor with a Ki of 1.7 mM (Table 1). In a study
of substrate derived peptides we determined the inhibition
constant of a heptapeptide containing the M cleavage site
6576 M. Buisson et al. / FEBS Letters 580 (2006) 6570–6578(positions P5–P2 0, compound 1, Table 1) ﬁrst, which had been
shown previously to be an eﬃciently cleaved substrate [24]. A
Dixon plot gave an inhibition constant Ki = 24 lM, while the
Cornish–Bowden plot showed parallel lines consistent with
pure competitive inhibition (not shown). As this peptide is a
substrate of the protease, the measured Ki value corresponds
to its Km [30]. In order to evaluate the importance of the N-ter-
minal part of the cleavage site, we tested pentapeptides corre-
sponding to positions P5–P1 derived from the M (compound
2) and R (compound 3) sites and found inhibition constants
of 4.1 mM and 1.2 mM, respectively. An a-keto-amide inhibi-
tor based on the M-site substrate of EBV protease (compound
4) showed an inhibitory constant Ki = 3.7 lM using the chro-
mogenic (Fig. 5) and 4 lM using the ﬂuorogenic assay. The
inhibition by compounds 5–8 has only been analysed in the
ﬂuorogenic assay yielding inhibition constants of 5–200 lM
(Table 1).4. Discussion
In the absence of citrate, the protease activity in function of
its total monomer concentration can be modelled by an equi-
librium between active dimers and inactive monomers as de-
scribed for other herpesvirus proteases [5–7]. The value of
the dissociation constant of 20 lM obtained from enzymatic
assays for the EBV protease dimer compares to a dissociation
constant of 57 lM obtained by analytical ultracentrifugation
[24]. Although the results probably agree within the experi-
mental errors of the ultracentrifugation experiment, it is
possible that the diﬀerence may be due to a protease construct
which carried two additional residues at the C-terminus
(Arg-Ser) which was used at the time of the ultracentrifugation
[24]. We showed later the crucial role for a correct C-terminus
as constructs carrying additional residues have a strongly
reduced catalytic activity and tend to aggregate [14]. In the
absence of citrate, the measurements of the apparent size of
the protease in function of its concentration by DLS are in
rough agreement with a monomer–dimer equilibrium (not
shown).
Sodium citrate, a kosmotropic agent, for example commonly
used as precipitant for protein crystallisation, has been shown
to strongly promote the activity of the EBV protease [24] and
lowered considerably the dissociation constant (in the range of
0.1–0.8 lM) as reported for other herpesvirus proteases (see
below). But whereas the concentration dependence of the spe-
ciﬁc activity vi/[E] of the enzyme could be very well described
by the theoretical curve in the absence of citrate or at low cit-
rate concentrations, ﬁts between model and data are rather
poor at citrate concentrations above 250 mM. Above an en-
zyme concentration of 0.5 lM, the value of vi/[E] rather
reaches a plateau value, which is diﬃcult to explain. The two
diﬀerent activity assays, a chromogenic and the more sensitive
ﬂuorogenic one led to very similar results.
It appeared that a competing eﬀect might inactivate the en-
zyme at high citrate concentrations leading to the apparent
plateau value, due to an auto-inhibition or the formation of
inactive oligomers as suggested from light scattering results
(Fig. 3). The majority of the enzyme appears to form dimers
or small oligomers as shown by the results from static light
scattering experiments (Fig. 3B). These experiments excluded
the presence of large amounts of large aggregates. The uncer-tainty about the fraction of active enzyme did not allow to de-
ﬁne a ktrue value for the rate of an active site as we did in the
absence of citrate.
The dissociation constant obtained in the presence of citrate
is comparable to the Kd = 0.23 lM [7] reported for the mono-
mer–dimer equilibrium of HSV1 protease at a citrate concen-
tration of 0.5 M. For CMV, the results of Margosiak et al.
[6] showed an activation of the enzyme in the presence of cit-
rate and suggested the existence of an additional aggregated
state, furthermore, the authors observed a similar eﬀect of cit-
rate and glycerol, where the increase of the catalytic eﬃciency
was more pronounced for citrate leading to a 26-fold increase
of kcat/Km at 800 mM. Margosiak et al. interpreted the rela-
tionship between activity and enzyme concentration in terms
of a monomer dimer equilibrium which is dramatically shifted
in presence of 25% glycerol (Kd = 8 lM in the absence of any
agent to 1.9 nM in the presence of 25% glycerol) accompanied
by a 3–6-fold increase of kcat/Km.
A common feature between EBV and CMV proteases is the
presence of a long disordered loop next to the active site (loop
L9, residues 121–135 in EBV [14], or 136–153 in CMV) which
is likely to be involved in substrate binding. This loop is poorly
ordered in the crystal structures and changes its conformation
upon substrate binding for CMV protease [31]. In the EBV
protease structure the loop is involved in the crystal contact
between the dimers. Conformational changes of this loop or
its interaction with other protease molecules in the presence
of citrate are likely to have an eﬀect on enzyme activity or
may promote further oligomerization.
For EBV protease, the aﬃnity for the substrate (Km =
0.9 mM) and the kcat = 14 min
1 are, respectively, decreased
and increased by factors of almost 3 and 6 in the presence of
0.5 M citrate, compared to the values in the absence of citrate
(Km = 2.6 mM, ktrue = 2.5 min
1) resulting in an about 17-fold
increase of the speciﬁcity constant kcat/Km (from 0.95 to
16.4 mM1 min1). This is comparable to the results from
Margosiak et al. for CMV protease [6].
The Km value of EBV protease in the absence of citrate is
similar to the ones obtained using pNA based substrates
with HCMV protease (substrate succinyl-AGVVNA-pNA,
kcat = 11 min
1, Km about 1.9 mM measured in the presence
of 20% glycerol and 10% DMSO, [32]) and HSV-1 protease
(LVLA-pNA, kcat = 20 min
1, Km = 2.0 mM in the presence
of 20 % glycerol [33]). Still the rate constant for EBV protease
in the absence of citrate is much lower than the ones described
but these assays contained glycerol which has also a stimula-
tory eﬀect [20]. When our results are compared to published
ones [19,20], at ﬁrst glimpse the activation by citrate appears
to be smaller, which is due to the fact that we compared the
ktrue rate constant of the active dimer. In the absence of citrate,
the fraction of active dimers at low enzyme concentrations is
very small and the apparent activation in the presence of
0.5 M citrate can be much higher due to the dimerization of
the enzyme.
In order to characterize further the substrate speciﬁcity of
the protease, we tested several peptides and peptidomimetics
derived from the natural cleavage sequences. Pentapeptides
corresponding to positions P5–P1 derived from the M
(compound 2, Table 1) and R sites (compound 3) yielded inhi-
bition constants of 4.1 mM and 1.2 mM, respectively, 170 or
respectively 50 times worse than the Ki of 24 lM for the sub-
strate heptapeptide obtained in competition experiments. This
M. Buisson et al. / FEBS Letters 580 (2006) 6570–6578 6577showed that residues from the P 0 side contribute to the aﬃn-
ity of the substrate. This agrees with the relatively ill-
deﬁned and open character of the binding pockets S5–S2
[14] whereas the sites P1 and P1 0 are located in a more pro-
nounced cleft and it is likely that in particular the serine res-
idue at position P1 0 contributes to the aﬃnity. The presence of
a hydrophobic group (pNA) C-terminal to the cleavage site as
present in the pNA-based chromogenic substrate (which has
been derived from the M site) conﬁrmed the importance of
a P1 0 residue for the aﬃnity because the Km (0.64 mM) is
smaller than the Ki of the peptidic part alone (4.1 mM),
although not as good as for the heptapeptidic substrate
(24 lM).
The introduction of hydrophobic groups on the C-terminal
side of the cleavage site has also been used to increase the aﬃn-
ity of peptide-based inhibitors containing an a-keto-amide
moiety between residues P1 and P1 0 which were reported for
the CMV protease [16,17,31]. Such inhibitors form a reversible
covalent complex through the serine residue of the catalytic
triad. The covalent complexes of two of them (IC050s of
<0.05 lM and 0.3 lM) with the CMV protease have been stud-
ied crystallographically [17,31]. Like the EBV enzyme, the hep-
atitis C protease NS3-4A has a relatively open catalytic site
which sparked a great interest in the development of a-keto-
amide based inhibitors [34,35]. Recently, the eﬃciency of the
a-keto-amide based anti-hepatitis-C-virus drug VX-950 [36]
was shown in phase Ib clinical trials where the compound
was administered orally.
We ﬁrst designed an inhibitor with a C-terminal a-keto-
amide group (compound 4, Table 1) based on the M-site sub-
strate of EBV protease, which showed an inhibition constant
of 4 lM. As pointed out above and as reported for the HCMV
protease [16], addition of interacting residues on the P 0 side
should increase the inhibitory potency of this class of com-
pounds toward the EBV protease. Although optimization of
a-keto-amide containing peptides may be diﬃcult to achieve,
they may be a promising class of inhibitors and we designed
ﬁrst inhibitors with an internal a-keto-amide group (com-
pounds 5 –8) and either a hydrophobic phenylalanine residue
or the natural substrate sequence at the C-terminus. Unexpect-
edly they did not show any potency increase compared to com-
pound 4 (Table 1). The presence of a serine residue in position
P1 0 is detrimental to the inhibition constant and part of the
aﬃnity is recovered by the introduction of an additional ala-
nine residue (compound 8) as present in the natural substrate
peptide (1). But despite of the covalently binding a-keto-
amide, the aﬃnity of inhibitor 8 is not increased over the nat-
ural substrate peptide (1). Probably the increased length of the
a-keto-amide compared to a peptide leads to an inadequate
positioning of the P 0 part of the peptide. The addition of
hydrophobic groups at the P1 0 position, which was suggested
by the better aﬃnity of the chromogenic substrate compared
to the peptide 2 led to compounds 6 (L-Phe in P1 0) and 5 (D-
Phe in P1 0) with inhibitory constants of 5 and 20 lM, respec-
tively, but did not improve the inhibitory potency compared
to the initial compound 4.
Due to the presence of the conserved cysteine 143 in the ac-
tive site [14] as well as the presence of the two histidine residues
of the catalytic triad, we postulated that the enzymatic activity
may be susceptible to zinc ions which could be chelated by
these residues as described for the CMV protease [22]. How-
ever, an elevated inhibition constant (1.7 mM, Table 1) wasobtained for ZnSO4 showing that zinc interfered only poorly
with enzyme activity.
In conclusion, the EBV protease activity assays in a 96-well
plate format combined with our characterisation of its mono-
mer–dimer equilibrium allows the accurate measurements of
the kinetic constants at a deﬁned oligomeric state. It provides
the basis for further screening of compounds with an inhibi-
tory action on EBV protease activity. Such compounds could
either target the active site such as optimized a-keto-amides
or other features of the protease such as the dimer interface.
The eﬀect of the kosmotropic agent sodium citrate, a represen-
tative of a series of stimulating agents commonly used in her-
pesvirus protease assays, on oligomerisation state and enzyme
activity has been characterized in detail. We showed that there
is a multifaceted eﬀect of citrate leading on one hand to an al-
most 100-fold reduction of the dimer dissociation constant and
on the other hand a stimulation of the enzymatic activity. For
the search for dimer-disrupting inhibitors of herpesvirus prote-
ases it may be better to carry out enzyme assays in the absence
of citrate.
Co-crystallization trials of the protease with a-keto-amide
based inhibitors with a C-terminal extension will be needed
in order to establish their mode of binding and to understand
their relatively poor inhibition. Still, the inhibition constant
of compounds with an a-keto-amide at the position of the
scissile bond can be in the micromolar range and further opti-
misation of these compounds may lead to promising inhibi-
tors.
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